This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Spectrum Blames Fusilev Sales Warning on Overstuffed Inventory

Spectrum says 75% of its Fusilev sales are derived from private oncology clinics, with the remaining 25% of sales coming from hospitals. Looking ahead, Keller explained demand for Fusilev from private oncology clinics was "stable" and could be reasonably projected to total approximately $25 million per quarter. The company is less confident about future hospital sales and Keller warned that sales there will continue to decline.

If Spectrum recorded $204 million in Fusilev sales last year, 75% coming from oncology clinics where demand is stable, why isn't the company able to forecast 2013 Fusilev sales of $150 million?

Because wholesalers current inventory is stuffed with Fusilev, making it impossible for Spectrum to know when new orders will start up again. Spectrum hopes to see wholesalers re-order Fusilev in the second quarter and into the second half of the year, but the company has no visibility into current wholesaler inventory level so it can't be sure, Keller said.

With the significant cuts in top-line revenue expected for 2013, Spectrum admitted on the Credit Suisse call that it will not be profitable unless expenses are cut. Spectrum net income for 2012 totaled $95 million, or $1.46 per share. In order to maintain non-GAAP profitability, Spectrum is cutting R&D expenses, although the company refused to elaborate on the conference call.

Shrotriya also tried to make the case that investors shouldn't abandon Spectrum. The company was undervalued when everyone thought Fusilev sales were great. Now that Fusilev sales have been whacked, the company is an even better buy, he insisted.

On Wednesday, few investors are buying what Shrotriya is selling.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
SPPI $5.89 -3.00%
AAPL $123.89 -0.43%
FB $81.43 -0.95%
GOOG $543.31 -0.86%
TSLA $188.79 0.01%

Markets

DOW 17,692.98 -83.14 -0.47%
S&P 500 2,056.65 -11.24 -0.54%
NASDAQ 4,861.4070 -39.4780 -0.81%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs